Leaf Biotech key facts
as of Oct 2026- Developer of the core monomer of bio-based new materials such as furandicarboxylic acid (FDCA) intended to assist in the development of a sustainable environment.
- Leaf Biotech is valued at approximately $198.6M as of Oct 2026 (last reported valuation).
- It has raised $42.0M; the latest was Later Stage VC ($13.9M) in Jul 2025.
- Notable investors include Hefei Industry Investment Group, Hefei Hi-Tech VC, Anyuan Fund, Ciit Asset Management, Amphora Capital China — 9 tracked in total.
- Status: Privately Held (backing).
Leaf Biotech's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·Watch Leaf Biotech: the Monday email on marks, rounds and moves
Leaf Biotech funding rounds
No funding rounds for Leaf Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Leaf Biotech valuation
Leaf Biotech's last reported valuation was $199 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Leaf Biotech investors
9 investors are on record for Leaf Biotech, including Hefei Industry Investment Group, Hefei Hi-Tech VC, Anyuan Fund and Ciit Asset Management.
About Leaf Biotech
Developer of the core monomer of bio-based new materials such as furandicarboxylic acid (FDCA) intended to assist in the development of a sustainable environment. The company develops new bio-based polyester material Polyethylene Furanoate (PEF) and its key intermediates, as well as green medicine and health care intermediates, providing sustainable biomass resources.
- Sector
- Materials and Resources
- HQ
- Hefei, China
- Founded
- 2014
- Employees
- 53
- Website
- leafbiotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.